上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (3): 295-.doi: 10.3969/j.issn.1674-8115.2011.03.010

• 论著（临床研究） • 上一篇    下一篇

p21、p53和c-erbB-2在非小细胞肺癌组织中的表达及临床意义

宋懿懿, 顾爱琴, 韩宝惠   

  1. 上海交通大学附属胸科医院肺内科, 上海 200030
  • 出版日期:2011-03-28 发布日期:2011-03-29
  • 通讯作者: 顾爱琴, 电子信箱: guaiqin11@126.com。
  • 作者简介:宋懿懿（1979—）, 女, 住院医师, 硕士生；电子信箱: lygasong@msn.com。

Expression of p21, p53 and c-erbB-2 in tissues of non-small cell lung cancer and its clinical significance

SONG Yi-yi, GU Ai-qin, HAN Bao-hui   

  1. Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China
  • Online:2011-03-28 Published:2011-03-29

PDF (PC)

1699

摘要：

目的 探讨p21、p53和c-erbB-2在非小细胞肺癌（NSCLC）组织中的表达及其临床意义。方法 收集经手术后病理学检查确诊的207例NSCLC患者的临床资料和存档石蜡组织标本。免疫组织化学方法检测肿瘤组织中p21、p53和c-erbB-2蛋白的表达情况，分析p21、p53、c-erbB-2蛋白表达的相关性及其与患者临床病理学特征的关系。结果 NSCLC组织中p21与p53表达呈显著正相关（r=0.245，P<0.01）。207例NSCLC组织标本中，p21、p53和c-erbB-2的阳性表达率分别为54.11%、38.16%和32.85%，其中低、中分化及有淋巴结转移患者明显高于高分化和无淋巴结转移患者（P<0.05）。p21和p53阳性表达率在有吸烟史、中央型和鳞癌患者中较高；c-erbB-2阳性表达率在女性、无吸烟史、周围型和腺癌患者中较高（P<0.05）。肿瘤组织中p21、p53和c-erbB-2表达阳性的患者5年生存率显著低于表达阴性的患者（P<0.05）。结论 p21、p53和c-erbB-2可能在NSCLC的发生和发展过程中起重要调控作用，可作为判断NSCLC患者预后的参考性指标。

关键词: p21, p53, c-erbB-2, 非小细胞肺癌

Abstract:

Objective To investigate the expression of p21, p53 and c-erbB-2 in tissues of non-small cell lung cancer (NSCLC), and explore its clinical significance. Methods The clinical data and paraffin tissue samples of 207 patients with NSCLC confirmed by postoperative pathology were collected. The expression of p21, p53 and c-erbB-2 protein in tissues of NSCLC was detected by immunohistochemical method, the correlation among the expression of p21, p53 and c-erbB-2 protein was analysed, and the relationship between the expression of p21, p53 and c-erbB-2 protein and clinicopathological characteristics was explored. Results The expression of p21 was significantly positively related to that of p53 in tissues of NSCLC （r=0.245，P<0.01）. The positive expression rates of p21, p53 and c-erbB-2 in tissues of NSCLC were 54.11%, 38.16% and 32.85%, respectively in 207 patients, and patients with poor differentiation, medium differentiation and lymph node metastasis had significantly higher expression than those with high differentiation and no lymph node metastasis (P<0.05). Patients with history of smoking, central type and squamous carcinoma had higher positive expression rates of p21 and p53, and females and those with no history of smoking, peripheral type and adenocarcinoma had higher expression rates of c-erbB-2 (P<0.05). The 5-year survival rates of patients with positive expression of p21, p53 and c-erbB-2 in tissues of NSCLC were significantly lower than those with negative expression (P<0.05). Conclusion p21, p53 and c-erbB-2 may play important roles in development and progression of NSCLC, which may serve as predicators for prognosis.

Key words: p21, p53, c-erbB-2, non-small cell lung cancer